GlassScriptPhysician profile
Joseph Ghata
NPI 1215258017
$45,104.43
in general payments reported to CMS, 2019-2025
16 companies · $21K in 2025
The $21K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.24 · 2020: $15.00 · 2021: $208 · 2022: $6,013 · 2023: $14K · 2024: $4,697 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Food and Beverage: $1,428 · Consulting Fee: $127 · Education: $41.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,181.00 |
| Food and Beverage | $1,427.67 |
| Consulting Fee | $126.55 |
| Education | $41.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $35,447.55 | 2021-2025 | |
| Amgen INC. | $8,745.61 | 2024-2025 | Tavneos, Krystexxa |
| Travere Therapeutics, INC. | $321.63 | 2021-2025 | |
| Baxter Healthcare | $136.02 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $129.30 | 2021 | |
| Novartis Pharmaceuticals Corporation | $105.62 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $55.02 | 2020-2024 | Jynarque |
| Aurinia Pharma U.S., INC. | $32.88 | 2021 | |
| Nxstage Medical, INC. | $26.81 | 2022 | |
| Glaxosmithkline, LLC. | $20.85 | 2025 | Benlysta |
| Ani Pharmaceuticals, INC. | $19.07 | 2024 | Purified Cortrophin Gel |
| Ardelyx, INC. | $17.65 | 2024 | Ibsrela |
| Akebia Therapeutics INC | $15.91 | 2025 | Vafseo, Auryxia |
| Novo Nordisk INC | $13.19 | 2024 | Rivfloza |
| Alexion Pharmaceuticals, INC. | $11.77 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $5.55 | 2024 | Tiopronin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ghata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.